氟尿嘧啶和奥沙利铂为基础的放化疗对局部晚期直肠癌患者的影响。
Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
机构信息
Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan.
Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
出版信息
In Vivo. 2021 Jan-Feb;35(1):593-601. doi: 10.21873/invivo.12296.
BACKGROUND/AIM: To evaluate the benefits of the addition of oxaliplatin (OX) to fluoropyrimidine (FP)-based neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancers (LARCs).
PATIENTS AND METHODS
We performed retrospective analyses comparing the pathological complete response (pCR) rate, overall survival (OS), recurrence-free survival (RFS), and local recurrence-free survival (LRFS) between FP-based and FP+OX-based CRT groups and for patients who had completed the CRT.
RESULTS
One hundred patients were included in the analyses: the pCR rate, OS, RFS, and LRFS were similar between these groups. The FP+OX group showed significantly more frequent incompleteness of the CRT compared to the FP group (p=0.049). Among the patients who had completed the CRT, the FP+OX group demonstrated significantly improved LRFS compared to the FP group (p=0.048).
CONCLUSION
The addition of OX to an FP regimen in neoadjuvant CRT for LARC may reduce local recurrence in patients who have achieved good compliance to CRT.
背景/目的：评估奥沙利铂（OX）联合氟嘧啶（FP）为基础的新辅助放化疗（CRT）对局部晚期直肠癌（LARC）患者的益处。
患者和方法
我们进行了回顾性分析，比较了 FP 为基础和 FP+OX 为基础 CRT 组以及完成 CRT 的患者的病理完全缓解（pCR）率、总生存（OS）、无复发生存（RFS）和局部无复发生存（LRFS）。
结果
共有 100 例患者纳入分析：两组的 pCR 率、OS、RFS 和 LRFS 相似。FP+OX 组与 FP 组相比，CRT 不完全的发生率明显更高（p=0.049）。在完成 CRT 的患者中，FP+OX 组的 LRFS 明显优于 FP 组（p=0.048）。
结论
在 LARC 的新辅助 CRT 中，FP 方案中加入 OX 可能会降低对 CRT 有良好依从性患者的局部复发率。
Zotero 插件